ClinicalTrials.gg
RecruitingNCT04075695UWFARVOUpdated Oct 18, 2023

Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion

An observational study in Retinal Vein Occlusion, sponsored by Renmin Hospital of Wuhan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by Renmin Hospital of Wuhan University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Retinal Vein Occlusion with a site in China — 8 open to participants now, 12 under way, 1 of them phase 3. Retinal Vein Occlusion · China.

Planned enrollment
10th of 11
60 · median 1,000
Started
2019
with 4 others
Observational
11 of 37
2 open now
Primary completion
2024-12
later than 3 of 11 live
Registered
13th of 37
by date
Lead sponsor
2 of 37
Renmin Hospital of Wuhan University

Among the 37 studies in Retinal Vein Occlusion with a site in China, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2019, is one of 11 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 13th registered.

Retinal Vein Occlusion

291 studies on the registry are indexed under Retinal Vein Occlusion; 33 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

8 of the 37 studies in Retinal Vein Occlusion with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Retinal Vein Occlusion studies recruiting now, 14 (74%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Retinal Vein Occlusion with a site in China, or all of them as a file.
02

Study summary

The changes of ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography (UWFA)

Read the detailed description

In this study, the ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion will be evaluated by ultra-wide field fluorescence angiography (UWFA). UWFA has a wider range than conventional angiography, and can clearly observe the peripheral retina. The purpose of this study is to quantitatively analyze these changes and investigate the effect on macular edema and neovascularization secondary to retinal vein occlusion.

03

Conditions studied

  • Retinal Vein Occlusion

Keywords

  • ischemic index
  • Ultra-wide field fundus fluorescein angiography
  • vascular leakage index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Chinese

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years or more
  2. Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema
  3. Duration of RVO not more than 4 months
  4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) which completely resolved (normalization of visual acuity and fundus examination) and who experienced a recurrence of RVO are also considered naive
  5. Patient who agrees to participate to the study and who has given his/her written,

Exclusion criteria

Exclusion Criteria:

  1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
  2. Active or suspected ocular or periocular infection
  3. Active severe intraocular inflammation
  4. RVO complicated with neovascularization
  5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
  6. Patient already included in the study for the treatment of the fellow eye
  7. Pregnant or breastfeeding woman
  8. Lack of effective for women of childbearing age
  9. Patient taking part in an interventional study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in non-perfused areas in different retinal area

    Change in non-perfused areas in different retinal area from Baseline to 1,2,3,6,9and 12 months

    Time frame: Baseline and1,2,3,6,9and 12 months

Secondary outcomes

  1. Change in best corrected visual acuity

    Change in best corrected visual acuity from Baseline to 1,2,3,6,9and 12 months

    Time frame: Baseline and1,2, 3, 6, 9 and 12 months

  2. Change in central macular thickness

    Change in central macular thickness from Baseline to 1,2,3,6,9and 12 months

    Time frame: Baseline and1,2, 3, 6, 9 and 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Dec 2024, 62 months after the start.

Of 26 observational studies under Retinal Vein Occlusion, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 69. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Sep 3, 2019
StartActual
Sep 18, 2019
Primary completionEst.
Dec 12, 2024
CompletionEst.
Aug 12, 2025
Last update
Oct 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04075695
Lead sponsor
Renmin Hospital of Wuhan University
Responsible party
Changzheng Chen (Chief of Department of Ophthalmology, Renmin Hospital of Wuhan University) — Principal investigator
First posted
Sep 3, 2019
Start date
Sep 18, 2019
Primary completion
Dec 12, 2024 (estimated)
Completion
Aug 12, 2025 (estimated)
Last update
Oct 18, 2023

Study contacts

CZ Chen, PHD
Contact
whuchenchzh@163.com
+86 13072765173
XL Wang
Contact
wangxl0807@163.com
+86 13117192316
Renmin Hospital of Wuhan University
principal investigator · Renmin Hospital of Wuhan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion